Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06255210
Status:
RECRUITING
Last Update Posted:
2024-02-13
First Post:
2024-02-04
Brief Title:
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma ESICON
Sponsor:
Hongmeng Yu
Organization:
Eye ENT Hospital of Fudan University
Study Overview
Official Title:
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma a Prospective Umbrella Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESICON
Brief Summary:
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma The main question it aims to answer is wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes Participants will be treated with different chemotherapy schemes to evaluate the tumor remission rate and long term survival
Detailed Description:
This study included patients with olfactory neuroblastoma who were pathologically diagnosed and met the criteria According to molecular profiles two different induction chemotherapy schemes were used to evaluate the tumor remission rate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None